After decades of clinical use as plasma expanders and efforts by hospital pharmacies to better regulate the use of albumin because of its high cost in many hospitals and countries [17], in a 1998 meta-analysis, albumin solutions were evaluated by one of the Cochrane Injuries Group Albumin Reviewers as an intervention potentially leading to increased mortality in patients with hypovolemia, burns, or hypoalbuminemia [18]. This evidence concerns the gene ALB and Hypovolemia.